EFPIA and CPIA sign memorandum of understanding formalising relationship between China and Europe’s research-based pharmaceutical industries
Brussels 29.05.13
The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the China Pharmaceutical Industry Association (CPIA) announced the signing of a Memorandum of Understanding (MoU) today, formalising the relationship between the two industry associations representing members operating in China, Europe and worldwide. The cooperation agreement will promote a continued exchange of knowledge and best practices that can support enhanced harmonisation and positively impact patients around the world.
“This is a step forward not only in cooperation between the industries in China and Europe, but a move towards fostering greater collaboration at global level,” said EFPIA Director General Richard Bergström. “It is critical that the European pharmaceutical industry continues a positive working relationship with strong emerging partners now – this is the time to act. Alongside our Chinese counterparts, we can enhance regulatory dialogues and work towards the international harmonisation of standards that will improve access to high-quality medicines and vaccines for patients in the future.”
“Taking steps that will allow Chinese pharmaceutical industries to keep pace with globalisation is one of CPIA’s core tasks,” said CPIA Executive President Zhen Hong. “EFPIA is an essential partner towards this end, and we are looking forward to a more comprehensive co-operation with EFPIA that will actively promote the integration of information and industry, and support modernisation of the Chinese pharmaceutical industry. We are determined to produce safer and more effectivepharmaceuticals that will contribute positively to patient health worldwide.”
The scope of the MoU includes a biennial meeting of the associations’ management and membership, regular exchanges of information on policy developments, and the organisation of expert events. By promoting the understanding of regulatory frameworks on both sides, EFPIA and CPIA intend to advance a productive working relationship that crosses international boundaries in the interests of patients worldwide.
About EFPIA:
EFPIA represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 39 leading pharmaceutical companies, EFPIA provides the voice of 1,900 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world. The pharmaceutical industry invests 27.5 billion on research and development per year in Europe and directly employs 660,000 people including 116,000 in R&D units in Europe.
EFPIA members are committed to delivering innovative medicines to address unmet needs of patients and reducing the burden of chronic diseases for Europe’s ageing population. EFPIA believes in close cooperation with its stakeholders to help create sustainable healthcare systems and to develop prompt responses to health threats in Europe.
About CPIA:
China Pharmaceutical Industry Association (CPIA) is a non-governmental, non-profit association founded in September 1988. Its members are mainly from large and medium sized pharmaceutical corporations, pharmaceutical device and packaging companies, regional pharmaceutical industry associations, research institutions, and academia, among others.
CPIA is committed to actively communicating and cooperating with domestic and foreign associations, making efforts to enhance China’s pharmaceutical industry, promoting healthy industry development, and improving the safety & efficacy of medicines to improve public health.
Media Contact:
Communication Team
EFPIA
Rue du Trone, 108
1050 Brussels
TEL: 0032.2.626.25.55
Email : communications@efpia.eu